Emcure Pharmaceuticals delivered a robust start to FY27, with consolidated net profit after tax (PAT) surging 36.2% year-on-year to ₹2,925 million for the quarter ended June 30, 2026. The strong bottom-line performance was driven by a 22.8% revenue growth to ₹25,804 million and significant operating leverage that expanded EBITDA margins by 50 basis points. Alongside the financial results, the company announced key leadership transitions: Satish Mehta will assume the role of Chairman post-AGM, while Samit Mehta has been appointed Chief Operating Officer (COO) with oversight of R&D and operations.

The Board of Directors approved the unaudited results on August 6, 2026, under Regulation 30 of the SEBI Listing Regulations. The figures were reviewed by the Audit Committee and subjected to a limited review by statutory auditors B S R & Co. LLP, who issued an unqualified conclusion.

Financial Performance

Revenue from operations reached ₹25,804 million, up from ₹21,005 million in Q1FY26. EBITDA grew 25.8% to ₹5,080 million, with margins improving to 19.7% from 19.2% previously. While gross margins contracted by 340 basis points to 58.4% due to a higher mix of international sales, the company effectively managed fixed costs, leading to a 110 basis point expansion in PAT margin to 11.3%. Profit before tax (PBT) rose 35.3% to ₹3,935 million.

Segment Growth Drivers

International business accounted for 58% of total revenue, growing 34.2% to ₹14,851 million. The Rest of World (RoW) segment was the standout performer, surging 44.8% to ₹5,218 million, driven by robust anti-retroviral (ARV) order books. Europe revenue expanded 32.8% to ₹5,367 million, aided by Liposomal Amphotericin B contributions, while Canada grew 24.6% to ₹4,266 million. Domestic sales increased 10.2% to ₹10,953 million, supported by brands in CNS, cardiology, and women’s health, alongside normalized performance from Zuventus Healthcare.

Strategic & Operational Updates

Emcure completed its acquisition of the remaining minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary effective July 21, 2026. Samit Mehta will lead Gennova as CEO. In R&D, spending rose to ₹904 million (3.6% of revenue), reflecting investments in new candidates like SHetA2 (anti-HPV) and alimatravir (HIV PrEP). Capital expenditure stood at ₹1,168 million. Net debt increased to ₹11,026 million, resulting in a net debt-to-trailing twelve-month EBITDA ratio of 0.6x. Return on Capital Employed (RoCE) remained stable at 23.4%.

What the Numbers Show

The divergence between gross margin compression and EBITDA expansion underscores Emcure’s operational efficiency. Despite gross margins falling by 340 basis points due to the lower-margin international mix, EBITDA margins widened. This indicates that productivity gains and fixed-cost absorption outpaced top-line dilution. Furthermore, the sharp acceleration in RoW revenue (44.8%) versus domestic growth (10.2%) highlights the increasing reliance on international markets for volume growth, a trend supported by the expansion of the ARV portfolio through strategic licensing agreements.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE168P01015/5483f164-be5e-4dbe-a8a2-ac9d223cc805.pdf

Emcure Pharmaceuticals delivered robust financial performance in Q1FY27, reporting a consolidated revenue of ₹26B, up from ₹21B in the same period last fiscal. The growth was primarily fueled by international operations, which expanded by 34.2% to ₹14,851 million, outpacing domestic sales that grew 10.2% to ₹10,953 million. Consolidated Profit After Tax (PAT) surged to ₹3B compared to ₹2B in the year-ago period, reflecting improved operating leverage and productivity gains. This strong start to FY27 marks the second year of the company's five-year strategic plan, signaling successful execution of its portfolio and integration initiatives.

The Board of Directors approved the unaudited financial results on August 06, 2026, pursuant to Regulation 30 of the SEBI Listing Regulations. The results were reviewed by the Audit Committee and subjected to a limited review by B S R & Co. LLP, the statutory auditors. Alongside financial disclosures, the Board transacted significant governance changes, including the retirement of Chairman Berjis Desai and the appointment of Managing Director & CEO Satish Mehta as the new Chairman effective from the conclusion of the ensuing Annual General Meeting (AGM) on September 21, 2026.

Financial Highlights

The following table summarises Emcure's key consolidated financial metrics for the quarter:

Domestic revenue accounted for 42.4% of total sales, supported by leading brands in CNS, cardiology, and women's health franchises. International revenue contributed 57.6%, with Europe growing 32.8% to ₹5,367 million, Canada rising 24.6% to ₹4,266 million, and Rest of World expanding 44.8% to ₹5,218 million. Gross margin contracted by 340 basis points to 58.4%, attributed to a higher share of international revenue and business mix shifts. However, this was offset by operating efficiency, resulting in EBITDA margin expansion to 20.64%.

Leadership and Corporate Developments

Mr. Berjis Desai, who served as Chairman and Non-executive Director, will cease to hold office at the conclusion of the AGM due to his appointment to the National Commission for Minorities. Consequently, Mr. Satish Mehta has been appointed as Chairman, retaining his role as Managing Director & CEO. Additionally, Mr. Raghu Kumar was appointed as an Additional Independent Director effective August 06, 2026, subject to shareholder approval at the AGM. Mr. Samit Mehta, Whole-time Director, was appointed Chief Operating Officer (COO) with immediate effect.

Strategic Acquisitions and R&D

Emcure completed the acquisition of the remaining 12.05% minority stake in Gennova Biopharmaceuticals Limited on July 21, 2026, making it a wholly owned subsidiary. Mr. Samit Mehta has been appointed CEO of Gennova. Furthermore, Gennova executed a Business Transfer Agreement on July 10, 2026, transferring its mRNA business undertaking for a cash consideration of ₹1,395 million. In Canada, subsidiary Mantra Pharma Inc. acquired 100% of Cutimed Inc. for up to CAD 5.05 million (₹337.54 million) to strengthen its dermatology portfolio.

What the Numbers Show

The divergence between gross margin contraction and EBITDA expansion highlights Emcure's operational discipline. While gross margins fell 340 basis points due to international mix, EBITDA margins rose to 20.64%, indicating that cost controls and productivity gains successfully absorbed the lower-margin international revenue mix. PAT growth significantly outpaced revenue growth, suggesting strong top-line conversion into bottom-line profits. International sales now constitute over half of total revenue, marking a structural shift in the company's geographic footprint.

Regulatory filings confirm compliance with Regulation 33 of the SEBI Listing Regulations. The statutory auditors issued an unqualified conclusion on both standalone and consolidated results. No dividend was declared for the quarter.